Medivir AB (MVIRb.F) Release: New Data From Simeprevir Phase III Studies Quest 1 and 2 in Hepatitis C Patients Will be Presented at EASL 23-28 April in Amsterdam
4/23/2013 11:49:18 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that data will be
presented on the investigational protease inhibitor simeprevir (TMC435) for the
treatment of genotype 1 hepatitis C patients.
These primary efficacy and safety results from two global phase III studies
demonstrate that use of the investigational protease inhibitor simeprevir led to
sustained virologic response 12 weeks after the end of treatment (SVR12) in 80
and 81 percent, respectively, of treatment-naïve genotype 1 chronic hepatitis C
adult patients with compensated liver disease, when administered once daily with
pegylated interferon and ribavirin. In both studies, 50 percent of patients
receiving pegylated interferon and ribavirin alone achieved SVR12.
Help employers find you! Check out all the jobs and post your resume.
comments powered by